{"transactions":[{"id":749388,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:05:04.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257371","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000119312526257371/ownership.xml","form_type":"4"}},{"id":1111293,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:00:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000095017025086110/ownership.xml","form_type":"4"}},{"id":1478751,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2024-06-14T20:30:06.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2024. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":2.77,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-073736","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000095017024073736/ownership.xml","form_type":"4"}},{"id":1840931,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2023-06-30T20:00:28.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 28, 2023. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":2.27,"expiration_date":"2033-06-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-040290","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000120919123040290/doc4.xml","form_type":"4"}},{"id":2099925,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":2.17,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2099924,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":4.72,"expiration_date":"2030-12-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2099923,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2099922,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":6.9,"expiration_date":"2028-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2099921,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":4.25,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2099920,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":7.75,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2099919,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:04.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":15.13,"expiration_date":"2026-08-17","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001062993-22-023029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023029/form4.xml","form_type":"4"}},{"id":2216908,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-07-01T20:59:52.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment to the Form 4 originally filed for the reporting person on June 23, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing."}],"balance_after":20000,"derivative":{"exercise_price":2.27,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-040302","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000120919122040302/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-23"}},{"id":2222914,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-06-23T21:01:51.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":20000,"derivative":{"exercise_price":2.27,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000120919122038967/doc4.xml","form_type":"4"}},{"id":2488454,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-02T19:00:30.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal monthly installments over one year from the date of grant."}],"balance_after":14000,"derivative":{"exercise_price":2.17,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001062993-21-012061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299321012061/form4.xml","form_type":"4"}},{"id":2663233,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2021-06-17T20:01:23.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":20000,"derivative":{"exercise_price":2.25,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-041393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000120919121041393/doc4.xml","form_type":"4"}},{"id":2937625,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T17:50:12.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal monthly installments over one year from the date of grant."}],"balance_after":12000,"derivative":{"exercise_price":4.72,"expiration_date":"2030-12-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001273636-20-000017","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363620000017/edgar.xml","form_type":"4"}},{"id":3110291,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2020-06-15T21:03:04.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":14210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":14210,"derivative":{"exercise_price":4.1,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":14210},"source":{"system":"sec-edgar","filing":"0000899243-20-016536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000089924320016536/doc4.xml","form_type":"4"}},{"id":3349594,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-06T18:14:43.000Z","date":"2019-12-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable on December 4, 2020."}],"balance_after":10000,"derivative":{"exercise_price":3.02,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001273636-19-000052","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363619000052/edgar.xml","form_type":"4"}},{"id":3490779,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T21:01:32.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":12700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer."}],"balance_after":12700,"derivative":{"exercise_price":0.68,"exercise_date":"2020-04-22","expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":12700},"source":{"system":"sec-edgar","filing":"0001437749-19-012107","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774919012107/rdgdoc.xml","form_type":"4"}},{"id":3490778,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T21:01:32.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.)."}],"balance_after":9000,"derivative":{"exercise_price":0.68,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001437749-19-012107","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774919012107/rdgdoc.xml","form_type":"4"}},{"id":3529539,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T21:00:45.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":47807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5582},"source":{"system":"sec-edgar","filing":"0000899243-19-013251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000089924319013251/doc4.xml","form_type":"4"}},{"id":3529538,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-05-13T21:00:45.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":107977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15401},"source":{"system":"sec-edgar","filing":"0000899243-19-013251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000089924319013251/doc4.xml","form_type":"4"}},{"id":3529537,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:45.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":5000,"price":10,"value":50000.0,"ownership":{"direct":true},"balance_after":25983,"source":{"system":"sec-edgar","filing":"0000899243-19-013251","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000089924319013251/doc4.xml","form_type":"4"}},{"id":3529536,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:45.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":20983,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":20983,"source":{"system":"sec-edgar","filing":"0000899243-19-013251","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000089924319013251/doc4.xml","form_type":"4"}},{"id":3534963,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-08T21:00:20.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":23684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 7, 2019, effective upon the pricing of the Issuer's initial public offering. This option is scheduled to vest as to (i) 50% of the underlying shares on the earlier of (A) the first anniversary of the date of grant and (B) the date of the first annual meeting of stockholders of the Issuer held following the date of grant and (ii) the remaining 50% of the underlying shares on the earlier of (A) the second anniversary of the date of grant and (B) the date of the second annual meeting of stockholders of the Issuer held following the date of grant."}],"balance_after":23684,"derivative":{"exercise_price":10,"expiration_date":"2029-05-06","underlying":"Common Stock","underlying_shares":23684},"source":{"system":"sec-edgar","filing":"0000899243-19-012649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000089924319012649/doc4.xml","form_type":"4"}},{"id":3758666,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-11-19T20:09:01.000Z","date":"2018-11-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable on November 15, 2019."}],"balance_after":10000,"derivative":{"exercise_price":6.9,"expiration_date":"2028-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001273636-18-000075","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000075/edgar.xml","form_type":"4"}},{"id":3858954,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-30T21:44:50.000Z","date":"2018-07-25","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being amended to correct a scrivener's error with regards to the number of shares underlying the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable on July 25, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4 is being amended to correct a scrivener's error with regards to the number of shares underlying the option grant."}],"balance_after":10000,"derivative":{"exercise_price":4.25,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001273636-18-000046","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000046/edgar.xml","form_type":"4/A","original_submission_date":"2018-07-27"}},{"id":3859883,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-27T18:04:59.000Z","date":"2018-07-25","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable on July 25, 2019."}],"balance_after":8000,"derivative":{"exercise_price":4.25,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001273636-18-000036","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000036/edgar.xml","form_type":"4"}},{"id":4136221,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.84,"expiration_date":"2024-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4136220,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":2652,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This Out of the Money Option, which became fully vested on December 31, 2013, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This Out of the Money Option, which became fully vested on December 31, 2013, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":50.88,"expiration_date":"2022-08-07","underlying":"Common Stock","underlying_shares":2652},"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4136219,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":2083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This Out of the Money Option, which became fully vested on April 19, 2012, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This Out of the Money Option, which became fully vested on April 19, 2012, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48,"expiration_date":"2021-04-19","underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4136218,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.76,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4136217,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger."}],"balance_after":0,"derivative":{"exercise_price":7.85,"expiration_date":"2023-12-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4136216,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.26,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4136215,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-11T15:19:48.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":12500,"price":1.52,"value":19000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028413/doc4.xml","form_type":"4"}},{"id":4274426,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T16:40:27.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units shall vest in full on the earlier of the one year anniversary of the grant or the next annual meeting of shareholders; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001274644-17-000056","document":"wf-form4_149816401149692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000127464417000056/wf-form4_149816401149692.xml","form_type":"4"}},{"id":4311211,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-22T19:29:33.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":20000,"price":0.49,"value":9800.0,"ownership":{"direct":true},"balance_after":105000,"derivative":{"exercise_price":0.49,"exercise_date":"2018-05-18","expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-17-009781","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774917009781/rdgdoc.xml","form_type":"4"}},{"id":4408927,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2017-03-02T19:21:21.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option becomes exercisable on February 28, 2018."}],"balance_after":8000,"derivative":{"exercise_price":7.75,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000899243-17-006163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000089924317006163/doc4.xml","form_type":"4"}},{"id":4512190,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-27T16:10:32.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date."}],"balance_after":9600,"derivative":{"exercise_price":8.65,"expiration_date":"2026-12-22","underlying":"Common Shares","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001104659-16-163884","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916163884/a4.xml","form_type":"4"}},{"id":4537856,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2016-12-01T16:05:50.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":4102,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 4,000 shares of Aegerion Pharmaceuticals, Inc. (\"Aegerion\") common stock pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, Aegerion and Isotope Acquisition Corp. (\"Isotope\"), pursuant to which Isotope was merged with and into Aegerion, effective November 29, 2016. On the date prior to the effective time of the merger, the closing price of Aegerion's common stock was $1.87 per share and the closing price of the Issuer's common shares was $1.83 per share."}],"balance_after":4102,"source":{"system":"sec-edgar","filing":"0001104659-16-160112","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916160112/a4.xml","form_type":"4"}},{"id":4538534,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T00:51:04.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":17.98,"exercise_date":"2016-06-26","expiration_date":"2025-06-26","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-16-159828","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000110465916159828/a4.xml","form_type":"4"}},{"id":4538533,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T00:51:04.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":5012,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":32.55,"exercise_date":"2015-06-26","expiration_date":"2024-06-26","underlying":"Common Stock","underlying_shares":5012},"source":{"system":"sec-edgar","filing":"0001104659-16-159828","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000110465916159828/a4.xml","form_type":"4"}},{"id":4538532,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T00:51:04.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":14700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":37.66,"exercise_date":"2016-04-26","expiration_date":"2023-04-26","underlying":"Common Stock","underlying_shares":14700},"source":{"system":"sec-edgar","filing":"0001104659-16-159828","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000110465916159828/a4.xml","form_type":"4"}},{"id":4538531,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-01T00:51:04.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of in exchange for 4,102 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. (\"QLT\") and Isotope Acquisition Corp. (\"Isotope\"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed \"Novelion Therapeutics Inc.\""}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-16-159828","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000110465916159828/a4.xml","form_type":"4"}}]}